Evidence map›Paper›PMID 31588234›Full record

ArticleTheranostics2019

A stage-specific cancer chemotherapy strategy through flexible combination of reduction-activated charge-conversional core-shell nanoparticles.

Lingfei Han, Yingming Wang, Xiaoxian Huang, Bowen Liu, Lejian Hu, Congyu Ma, Jun Liu, Jingwei Xue, Wei Qu, Fulei Liu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics.Biochimica et biophysica acta. Reviews on cancer · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lingfei HanDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Yingming WangDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Xiaoxian HuangDepartment of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
Bowen LiuDepartment of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
Lejian HuDepartment of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
Congyu MaDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Jun LiuThe Joint Laboratory of Chinese Pharmaceutical University and Taian City Central Hospital, Taian City Central Hospital, Taian, 271000, China.
Jingwei XueThe Joint Laboratory of Chinese Pharmaceutical University and Taian City Central Hospital, Taian City Central Hospital, Taian, 271000, China.
Wei QuDepartment of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
Fulei LiuDepartment of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
Feng FengDepartment of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China.
Wenyuan LiuDepartment of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision medicine has increased the demand for stage-specific cancer chemotherapy. Drugs with different properties are needed for different stages of tumor development, which is, inducing rapid destruction in the early stage and facilitating deep penetration in the advanced stage. Herein, we report a novel reduction-activated charge-conversional core-shell nanoparticle (CS NP) formula based on ring-closing metathesis of the thiamine disulfide system (TDS) to deliver the chemotherapeutic agent-gambogic acid (GA).

Indexed as

AnimalsAntineoplastic AgentsCarcinoma, HepatocellularDrug Delivery SystemsDrug LiberationHep G2 CellsHumansHyaluronic AcidInjections, IntravenousLiver NeoplasmsMaleMice, Inbred ICRNanoparticlesOxidation-ReductionSpheroids, CellularThiamineAntineoplastic Agentsgambogic acidHyaluronic AcidThiaminethiamine disulfideTretinoinXanthonescharge conversionhepatocellular carcinomareduction-activatedstage-specific chemotherapytumor penetration

Identifiers

PMID31588234
PMCPMC6771249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.